We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Epigenomics Signs Nonexclusive Licensing Agreement for Septin9

By LabMedica International staff writers
Posted on 09 Jul 2012
Print article
Epigenomics AG (Berlin, Germany), a cancer molecular diagnostics company, signed a nonexclusive licensing agreement for its DNA methylation biomarker Septin9 with Companion Dx Reference Lab (Houston, TX, USA).

Under the terms of the agreement, Companion Dx has obtained rights to establish and commercialize a blood-based, laboratory-developed test (LDT) using methylated Septin9 as biomarker for the detection of colorectal cancer. Epigenomics is entitled to double digit royalties on sales.

The v2 region of the Sept9 promoter is methylated in colorectal cancer tissue compared with normal colonic mucosa. Using highly sensitive real time polymerase chain reaction (PCR) assays, methylated Sept9 was detected in the blood of colorectal cancer patients. This alternate methylation pattern in cancer samples is suggestive of an aberrant activation or repression of the gene compared to normal tissue samples.

The agreement with Companion Dx complements Epigenomics’ LDT agreements with Quest Diagnostics, (Madison, NJ, USA), Arup Laboratories (Salt Lake City, UT, USA), and Warnex Medical Laboratories (Laval, QC, Canada) in North America. In addition, Abbott Molecular (Des Plaines, IL, USA) has a worldwide, nonexclusive license to develop and to commercialize IVD test kit products while Qiagen (Hilden, Germany) and Sysmex (Kobe, Japan) have acquired options to do so.

Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of products for the screening and diagnosis of cancer. The company's lead product, Epi proColon, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the USA.

Companion Dx Reference Lab specializes in pharmacogenomics testing and cancer companion diagnostics. Personalized pharmacogenomic evaluations reveal the patient's risks for serious side effects and reduced drug effectiveness, allowing the physician to make clinical decisions that improve therapeutic outcomes prior to therapy.

Related Links:
Epigenomics AG
Companion Dx Reference Lab





Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston)

AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell

Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.